Factors Affecting the Deposition of Inhaled Porous Drug Particles

Musante, Cynthia J.; Schroeter, Jeffry D.; Rosati, Jacky; Crowder, Timothy M.; Hickey, Anthony; Martonen, T. B.

doi:10.1002/jps.10152

Cited by 89 publications

(46 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For a constant flow rate, as the inspiratory volume increases, the time of breathing increases, therefore enhancing the time for particle deagglomeration. An inspiratory volume of 3 l with an inhalation rate of 60 l/min resulted in the highest deposition in the pulmonary region of the lung [55].…”

Section: Inspiratory Airflowmentioning

confidence: 96%

Lactose characteristics and the generation of the aerosol

Pilcer¹,

Wauthoz²,

Amighi³

2012

Advanced Drug Delivery Reviews

179

113

View full text Add to dashboard Cite

Section: Inspiratory Airflowmentioning

confidence: 96%

Lactose characteristics and the generation of the aerosol

Pilcer¹,

Wauthoz²,

Amighi³

2012

Advanced Drug Delivery Reviews

179

113

View full text Add to dashboard Cite

“…For instance, micrometre-sized particles are important in passive drug targeting such as pulmonary drug delivery. They are suitable for incorporation into aerosols which have potential uses for inhalation devices in the treatment of asthma (Edwards et al 1997;Musante et al 2002;Chowdary & Rao 2004). Nanometre-sized particles also have certain unique applications in drug delivery (Monsky et al 1999) in that they can penetrate small capillaries, allowing enhanced accumulation of nanoparticles at delivered target sites.…”

Section: Introductionmentioning

confidence: 99%

Size mapping of electric field-assisted production of polycaprolactone particles

Enayati

Ahmad

Stride

et al. 2010

J. R. Soc. Interface.

View full text Add to dashboard Cite

In this investigation, biodegradable polycaprolactone polymeric particles (300-4500 nm in diameter) were prepared by jetting a solution in an electric field. An extensive study has been carried out to determine how the size and size distribution of the particles generated can be controlled by systematically varying the polymer concentration in solution (and thereby its viscosity and electrical conductivity), and also the selected flow rate (2-50 ml min 21) and applied voltage (0-15 kV) during particle generation. Change in these parameters affects the mode of jetting, and within the stable cone-jet mode window, an increase in the applied voltage (approx. 15 kV) resulted in a reduction in particle size and this was more pronounced at high flow rates (such as; 30, 40 and 50 ml min 21 ) in the same region. The carrier particles were more polydisperse at the peripheral regions of the stable cone-jet mode, as defined in the applied voltage-flow rate parametric map. The effect of loading a drug on the particle size, size distribution and encapsulation efficiency was also studied. Release from drug-loaded particles was investigated using UV spectrophotometry over 45 days. This work demonstrates a powerful method of generating drug-loaded polymeric particles, with the ability to control size and polydispersivity, which has great potential in several categories of biotechnology requiring carrier particles, such as drug delivery and gene therapy.

show abstract

“…The mucus barrier, metabolic enzymes in the tracheobronchial region and macrophages in the alveoli are the main barriers for penetration of drugs. Particle size is a major factor determining the diffusion of nanoformulation in the bronchial tree, with particles in the nano-sized region more likely to reach the alveolar region and particles with diameters between 1 and 5 μm expected to deposit in the bronchioles (Musante et al, 2002;Patton and Byron, 2007). A limit to absorption has been shown for larger particles, presumably because of an inability to cross the air-blood barrier (Ryan et al, 2013).…”

Section: Alternative Administration Routesmentioning

confidence: 99%

Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling

Moss

Siccardi

2014

British J Pharmacology

View full text Add to dashboard Cite

The delivery of therapeutic agents is characterized by numerous challenges including poor absorption, low penetration in target tissues and non-specific dissemination in organs, leading to toxicity or poor drug exposure. Several nanomedicine strategies have emerged as an advanced approach to enhance drug delivery and improve the treatment of several diseases. Numerous processes mediate the pharmacokinetics of nanoformulations, with the absorption, distribution, metabolism and elimination (ADME) being poorly understood and often differing substantially from traditional formulations. Understanding how nanoformulation composition and physicochemical properties influence drug distribution in the human body is of central importance when developing future treatment strategies. A helpful pharmacological tool to simulate the distribution of nanoformulations is represented by physiologically based pharmacokinetics (PBPK) modelling, which integrates system data describing a population of interest with drug/nanoparticle in vitro data through a mathematical description of ADME. The application of PBPK models for nanomedicine is in its infancy and characterized by several challenges. The integration of property-distribution relationships in PBPK models may benefit nanomedicine research, giving opportunities for innovative development of nanotechnologies. PBPK modelling has the potential to improve our understanding of the mechanisms underpinning nanoformulation disposition and allow for more rapid and accurate determination of their kinetics. This review provides an overview of the current knowledge of nanomedicine distribution and the use of PBPK modelling in the characterization of nanoformulations with optimal pharmacokinetics. LINKED ARTICLESThis article is part of a themed section on Nanomedicine. To view the other articles in this section visit http://dx

show abstract

Factors Affecting the Deposition of Inhaled Porous Drug Particles

Cited by 89 publications

References 29 publications

Lactose characteristics and the generation of the aerosol

Lactose characteristics and the generation of the aerosol

Size mapping of electric field-assisted production of polycaprolactone particles

Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling

Contact Info

Product

Resources

About